The number of women under age 40 diagnosed with basal cell carcinoma has more than doubled in the last 30 years; the squamous cell carcinoma rate for women has also increased significantly.
Combination antibody therapy shows promise in metastatic melanoma (Science Daily)
A duo of monoclonal antibodies -- ipilimumab and bevacizumab -- each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial.
- About Us
- Skin Cancer
- Member Section